Search
Avalo Therapeutics Inc
AVTXAdd to Watchlist
7.440USD
+0.320+4.49%
Close 10-28 16:00（ET）
399.01MMarket Cap
LossP/E TTM
Avalo Therapeutics Inc (AVTX) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Avalo Therapeutics Inc in the past month.
Strong Buy
8 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
44.909USD+563.35%
AVTX Analyst Recommendation Trends
In the current month, AVTX has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the last month is 44.909.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
8
8
8
7
6
5
5
4
6
6
7
7
7
7
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
15
14
13
12
11
10
AVTX Analyst Rating for Peer Comparison
Updated: Oct 29, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, AVTX EPS is projected to reach -0.616 in FY2026Q3, following reported EPS of -0.834 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.46
-1.03
-0.58
-0.62
-0.57
Actual
-0.75
-0.98
-0.83
--
--
Surprise
+48.60%
+4.81%
-43.32%
--
--
FAQs
What is Avalo Therapeutics Inc's price target?
Analysts forecast that Avalo Therapeutics Inc's price target is USD 38.91, with the highest forecast at USD 60.00 and the lowest forecast at USD 10.00.
How have Avalo Therapeutics IncAVTX's recent earnings per share performed?
The market expectation was USD -0.83, while Avalo Therapeutics IncAVTX's earnings per share (EPS) for the previous quarter was USD -0.98. EPS for the next quarter is expected at USD -0.62.
What is the analyst rating for Avalo Therapeutics Inc?
Based on the ratings of Avalo Therapeutics Inc's stock from 14 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.